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Introduction
Estrogen mediates a broad spectrum of physiologic functions
ranging from regulation of the menstrual cycle and reproduction
to the modulation of bone density and cholesterol transport.The
case for estrogen supplementation following menopause was
based on the clinical observations that elderly women without
circulating sex steroids had a higher incidence of osteoporotic
fractures, coronary heart disease (CHD) and, most importantly
for quality of life, hot flashes and night sweats. Conjugated
equine estrogen alone was supplemented with medroxyproges-
terone acetate to reduce the risk of endometrial cancer in post-
menopausal women, and the combination is referred to as
hormone replacement therapy (HRT). A regimen of HRT is
effective in reducing osteoporotic fractures and is indispensable
in treating severe menopausal symptoms (WGWHII, 2002).
However, recent prospective clinical trials demonstrate that
long-term HRT, i.e., 5 years or more, provides no overall benefit
for women’s health (MWSC, 2003; WGWHII, 2002). Although
there are reductions in the incidence of colon cancer, osteo-
porotic fractures, and menopausal symptoms, there are
increases in breast cancer, Alzheimer’s disease, strokes, and
blood clots (Figure 1; Chlebowski et al., 2003; MWSC, 2003;
Shumaker et al., 2003; WGWHII, 2002). These definitive clinical
studies have highlighted the opportunities for innovation in the
selective modulation of estrogen target tissues (Figure 1).
Estrogen action at target sites around the body is mediated
through related but distinct estrogen receptors (ERs) designat-
ed ERα and β (Enmark and Gustafsson, 1999). Estrogens bind
to the ligand binding domain of the ER to induce a conforma-
tional change in protein structure that permits the subsequent
dimerization and interaction with coactivator molecules (Figure
2; McDonnell and Norris, 2002; McKenna et al., 1999). The
sequential activation of genes occurs through multiple mecha-
nisms either directly at estrogen response elements in the pro-
moter region of estrogen-responsive genes or through a
tethering protein-protein interaction with cfos/jun B (AP-1) sites
or Sp1 sites (Figure 2). These cellular signal transduction path-
ways can potentially be exploited to amplify tissue response
selectivity. Alternatively, survival pathways in cancer could
evolve to alter the entire responsiveness to ER signaling.
Traditionally, the science of pharmacology plays a critical
role in drug discovery by using a receptor target to identify
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Extended exposure to the selective estrogen receptor modulators (SERMs) such as raloxifene to prevent osteoporosis and
tamoxifen or the aromatase inhibitors to treat or prevent breast cancer are established therapeutic strategies. However, there
are now clearly defined consequences of exhaustive antihormonal therapy in breast cancer. Ultimately, drug resistance to
SERMs and aromatase inhibitors enhances cancer cell survival but a paradoxical supersensitivity to estrogen action devel-
ops that causes cancer cell apoptosis. The future exploitation of these novel data will allow selective killing of cancer with
fewer side effects for patients.
Figure 1. Progress toward an ideal SERM
The overall good or bad aspects of administer-
ing hormone replacement therapy to post-
menopausal women compared with the
observed site-specific actions of the selective
estrogen receptor modulators tamoxifen and
raloxifene. The known beneficial or negative
actions of selective estrogen receptor modula-
tors (SERMs) have opened the door for drug dis-
covery to create the ideal SERM or targeted
SERMs to either improve quality of life or prevent
diseases associated with aging in women.
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select molecules for testing in the clinic. However, the recogni-
tion of the target tissues concept of selective estrogen receptor
modulation by compounds originally referred to as nonsteroidal
antiestrogens (Jordan, 1984) was noted first in laboratory ani-
mals and then successfully translated to the clinic (Jordan,
2001).
The clinical application of the SERM concept
The recognition of the SERM concept is an example of transla-
tional research that changed medical practice. Although the tar-
geting of the ER with the nonsteroidal antiestrogen tamoxifen
has increased selective survivorship in breast cancer (Jensen
and Jordan, 2003), the strategic application of long-term anti-
hormonal treatments (Jordan and Allen, 1980) has created 
an important increase in disease-free and overall survival
(EBCTCG, 1998; Goss et al., 2003). However, tamoxifen is not a
complete or pure antiestrogen, and the drug exhibits partial
estrogen-like actions that could produce a suboptimal blockade
of estrogen-stimulated breast tumor growth. Currently, aro-
matase inhibitors to produce an estrogen-free environment are
demonstrating superiority to tamoxifen in controlling the growth
of ER-positive breast cancer (ATAC Trialists’ Group, 2002). Most
importantly, the use of aromatase inhibitors for the treatment of
breast cancer avoids some of the estrogen-like side effects
observed in patients treated with tamoxifen. Tamoxifen is a par-
tial estrogen agonists in the rodent uterus. Laboratory studies
subsequently demonstrated that tamoxifen had the potential to
stimulate growth of endometrial cancer but inhibit the growth of
breast cancer (Gottardis et al., 1988).These data translated to a
low but significant increase in the incidence of endometrial can-
cer in postmenopausal women treated with tamoxifen (Fisher et
al., 1994; Fornander et al., 1989). However, the incidence of
endometrial cancer is reduced during treatment with an aro-
matase inhibitor (ATAC Trialists’ Group, 2002).
Clearly, the fact that tamoxifen increases the incidence of
endometrial cancer is a significant concern for the application of
tamoxifen as a chemopreventive for breast cancer in high-risk
women. Nevertheless, the possibility that an antiestrogen could
increase the risk for osteoporosis in well women was initially of
greater concern for women’s health in the 1980s. Tamoxifen
maintains bone density in ovariectomized rats (Jordan et al.,
1987; Turner et al., 1987), and this result translated to maintain-
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Figure 2. Complexity of SERM signal transduction
The decision network for estrogen or SERM action binding to nuclear estrogen receptor (ER) α or β receptor or membrane ER (decision 1). Receptor-specif-
ic or mixed specificity ligands bind to the ligand binding domain (E region) of the ERs to cause a ligand-specific perturbation in the receptor complex that
creates opportunities for the complex to bind either coactivators or corepressors on the external surface (decision 2). The interactive proteins shunt the ER
complex into transcriptionally active or inactive states. Although the expanding family of coregulators are being defined, this does not exclude the possi-
bility of other interactive proteins could alter gene transcription through phosphorylation activation. This could be initiated rapidly either by membrane ER
or constitutively through cell surface growth factor receptors. The next decision point (3) is where the complex or coregulators are ubiquitated and
destroyed by the proteasome or accumulate to become promiscuous estrogen-like complexes. Again, phosphorylation may play an important role in the
activity of the ER complex. The decision (4) to interact with the machinery involved with gene transcription can shunt the signaling pathway from positive or
negative regulation based upon the ER concerned, the ligand, or whether there is a direct interaction with an estrogen response element (ERE) or a teth-
ered interaction to proteins at AP-1 or SP-1 sites. Overall, the decision network creates a complex regulatory system at target tissues or in cancer where a
growth advantage can be exploited in response to antiestrogen therapies.
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ing bone density in postmenopausal patients (Love et al., 1992)
with a nonsignificant reduction in fractures in a chemopreven-
tion trial (Fisher et al., 1998). Thus, women with an increased
risk for breast cancer treated with tamoxifen can anticipate a
50% reduction in the incidence of breast cancer (antiestrogenic)
but a reduction of osteoporotic fractures (estrogenic) and an
increase in the side effects of blood clots and endometrial
polyps and cancer (estrogenic) (Figure 1; Fisher et al., 1998).
This spectrum of SERM action creates a requirement for an
intervention focused only on very high-risk women and a
requirement for new SERM discovery programs.
However, there is difficulty in identifying target populations
in breast cancer. Clearly, a broader strategy was required to
enhance the potential of SERMs in women’s health to prevent
breast cancer. The approach that was taken was to exploit the
potential of SERMs to reduce osteoporotic fractures but with the
beneficial side effect of reducing the incidence of breast cancer
(Lerner and Jordan, 1990). The result is raloxifene, originally a
discarded breast cancer drug named keoxifene. Raloxifene
(keoxifene) maintains bone density in ovariectomized rats
(Jordan et al., 1987) and prevents carcinogen-induced rat mam-
mary carcinogenesis (Gottardis and Jordan, 1987). These data
subsequently translated to the clinic where raloxifene is effec-
tive at reducing osteoporotic fractures in women at risk (Ettinger
et al., 1999) with a reduction by 70% in the incidence of breast
cancer (Cummings et al., 1999). Raloxifene is currently avail-
able for the prevention of osteoporosis but with breast and
endometrial safety. Raloxifene is also being evaluated for the
ability to reduce the incidence of coronary heart disease
(Mosca et al., 2001).
There is considerable interest in developing new SERMs as
multifunctional agents in women’s health (Jordan, 2003a,
2003b). However, the approach for the future will be based on
the molecular modulation of emerging mechanisms rather than
what happened in the past with the reinvention of nonsteroidal
antiestrogens as receptor-targeted therapeutics from their orig-
inal application as modulators of fertility (Jordan, 2003c).
Mechanisms of SERM action
The interpretation of a novel SERM at a target site involves a
complex series of decision points that could shunt the receptor
complex in one direction or another (Figure 2). The challenge is
first to document fully the machinery available at target sites
and then to understand the subcellular network of outcome
opportunities. At present our basic understanding of the
process is fragmentary, but current knowledge provides a rea-
sonable basis for evaluating future targeted therapeutics
(Figure 2).
The target site distribution of ERα and ERβ and differential
ligand specificity and pharmacology (Enmark and Gustafsson,
1999) have created opportunities to develop receptor-specific
ligands based primarily on differences in receptor affinity
(Meyers et al., 2001; Stauffer et al., 2000). It is possible to envi-
sion the development of an ERα-specific antagonist to prevent
breast cancer or an ERβ-specific agonist to enhance CNS func-
tions or prevent colon cancer. However, the process of drug
development based on receptor screening may be confounded
by the complexities of the subsequent signal transduction path-
ways (Figure 2).
Considerable progress has been made during the past 5
years in understanding the molecular perturbations that occur
in the ligand binding domain of ERα and β when complexed with
a SERM (Brzozowski et al., 1997; Pike et al., 2001; Shiau et al.,
1998). The essential structural determinant of the SERM mole-
cule is a correctly positioned alkylaminoethoxyphenyl side chain
that interacts with asp351 in ERα to modulate antiestrogenic
action through corepressor binding to the external surface of
the SERM receptor complex (Brzozowski et al., 1997; Shiau et
al., 1998). The interaction of the SERM side chain with asp351
allosterically modulates the estrogenic and antiestrogenic
action of tamoxifen and raloxifene. The tamoxifen ERα complex
is much more promiscuous and estrogen-like than the ralox-
ifene ERα complex, but estrogen and antiestrogen actions can
be modulated by mutating asp351 (Liu et al., 2002; MacGregor
Schafer et al., 2000). The interpretation of molecular studies
could go some way to explaining the enhanced estrogen-like
actions of tamoxifen in the uterus compared with raloxifene
(Figure 1; Cummings et al., 1999; Fisher et al., 1998).
Nevertheless, recent experimented evidence suggests that
there is another dimension involved in the estrogen-like action
of SERMS.
The relative concentration of members of the coactivator
family (SRC-1, -2, or -3) or corepressors may regulate the
response of a tissue to ERα. One possibility to explain target
site specificity for SERM action would be to have site-specific
coactivator interactions. Shang and Brown (2002) demonstrat-
ed, in one uterine cell line, that elevated SRC-1 enhanced the
estrogen-like actions of 4-hydroxytamoxifen but not raloxifene.
This effect was not noted in breast cancer cells.
Ultimately, the response of a tissue to a ligand-receptor
complex will depend not only on the efficacy but also the con-
centration of receptor complexes available to interact with the
gene regulatory machinery. This consideration draws into the
equation the dimension of receptor complex destruction. The
higher the level of low-efficacy complexes, the higher the proba-
bility of estrogen action. However, the efficacy and concentra-
tion of the activated ligand receptor complex is regulated not
only by sensitivity to ubiquitization of ER (Wijayaratne and
McDonnell, 2001) and subsequent destruction; the amount of
coactivator proteins (Lonard et al., 2004) is also important to
amplify or suppress the activation of a complex.
SERMs increase the levels of SRC-1 and -3 and also
enhance the transcriptional activity of nuclear receptors other
than ER in SERM-treated cells (Lonard et al., 2004). These
events create additional opportunities for understanding the
complexity of target site specificity with SERMs. Indeed, tamox-
ifen-induced increases in SRC-3 have previously been shown to
occur through the indirect action of SERM-induced transforming
growth factor β (Lauritsen et al., 2002). However, the complex
preparations for gene transcription or protein activation are not
the final decision the SERM or estrogen must make. There
appear to be numerous additional pathways that can modulate
the individual cells in a target tissue. The simplistic view that the
ER complex activates genes through interaction with an ERE in
the promoter region has evolved dramatically over the past
decade. It seems that the promoter region can influence the
shape of the ER complex, which in turn can alter the external
shape of an ER complex and, as a result, coactivator or core-
pressor binding (Hall et al., 2002). Select genes could be
sequentially regulated by the changing conformation of an ER
complex being modulated by promoter interactions.
It is now recognized that the SERM ER complex is extreme-
ly promiscuous and can also activate genes through AP-1
(Webb et al., 1995) and SP-1 (Khan et al., 2003) (Figure 2) pro-
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tein-protein interactions, and cell survival cascades may also be
modulated by ER located in the cell membrane (Razandi et al.,
1999). Most importantly, the bidirectional signaling between cell
surface receptors (insulin-like growth factor and epidermal
growth factor receptors) and ER will have profound effects on
estrogen and SERM signaling opportunities (Levin, 2003).
These membrane pathways can rapidly activate both ER and
coactivators to enhance cell replication.
Overall, normal cells and tissues have the potential to be
modulated by SERMs through a diverse and complex network
of decision pathways. Understanding the potential targets will
enhance the chances of novel designer SERMs to regulate or
modulate numerous physiologic conditions. However, unlike the
normal cell, the cancer cell adapts and evolves through selec-
tion in a changing drug environment. Understanding drug resis-
tance to SERMs now creates new opportunities to exploit
emerging discoveries in cancer cell regulatory pathways.
The evolution of drug resistance to SERMs
Twenty years ago, the development of drug resistance to anti-
hormonal therapy in breast cancer was viewed as the insensi-
tive ER-negative cells overgrowing ER-positive cells that were
in growth arrest from antiestrogen treatment. Today, the conver-
sation between the laboratory and the clinic has advanced ther-
apeutics by recognizing various forms of drug resistance to
tamoxifen. Current research is targeting resistance mecha-
nisms to develop new therapeutic strategies. Resistance can be
classified as either intrinsic resistance, where ER-positive
breast cancer is initially refractory to antiestrogen treatment, or
ER-positive disease that initially responds to antihormonal
treatment but acquired resistance occurs subsequently.
Acquired resistance can be caused by alterations in the ER sig-
nal transduction pathway converting the inhibitory SERM ERα
complex to a growth stimulatory signal. Recent clinical studies
(Osborne et al., 2003) indicate that tamoxifen is unlikely to be
an effective therapy in ER-positive breast cancer patients who
also have high levels of SRC-3 and HER2/neu. The cell surface
signaling pathway can enhance phosphorylation of both the ER
and SRC-3 (Font de Mora and Brown, 2000). Thus, the multiple
opportunities to initially (intrinsic resistance) or eventually
(acquired resistance) subvert the inhibitory actions of the
tamoxifen ER complex creates a complex survival system for
the cancer cell. This insight into the tumor options of either
estrogen or tamoxifen-stimulated growth has resulted in
improvements in therapeutics with either aromatase inhibitors
that create a “no-estrogen” environment (ATAC Trialists’ Group,
2002) or the pure antiestrogen fulvestrant (ICI 182,780) that
destroys the ER (Wijayaratne and McDonnell, 2001). Both drug
types are valuable for the treatment of tamoxifen-resistant
breast cancer (Robertson et al., 2003).
However, current understanding of drug resistance to
SERMs or estrogen deprivation is based on short-term (1–2
years) treatment periods. This treatment strategy was appropri-
ate 25 years ago when the focus was on treating advanced dis-
ease, but today all trends are toward a decade of treatment in
breast cancer (Goss et al., 2003) or indefinite treatment with
raloxifene for the prevention of osteoporosis. Recently, the
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Figure 3. The evolution of drug resistance to SERMs
Acquired resistance occurs during long-term treatment with a SERM and is
evidenced by SERM-stimulated breast tumor growth. Tumors also continue
to exploit estrogen for growth when the SERM is stopped, so a dual signal
transduction process develops. The aromatase inhibitors prevent tumor
growth in SERM-resistant disease and fulvestrant that destroys the ER is also
effective. This phase of drug resistance is referred to as Phase I resistance.
Continued exposure to a SERM results in continued SERM-stimulated
growth, but eventually autonomous growth (Phase III) occurs that is unre-
sponsive to fulvestrant or aromatase inhibitors. The event that distinguishes
Phase I from Phase II acquired resistance is a remarkable switching mecha-
nism that now causes apoptosis, rather than growth, with physiologic levels
of estrogen. These distinct phases of laboratory drug resistance (Lewis et
al., 2004; Yao et al., 2000) have their clinical parallels and this new knowl-
edge is being integrated into the treatment plan.
Figure 4. Life and death of Phase II SERM
resistance
Putative mechanisms of estradiol (E2)-induced
apoptosis that occurs after the switch point in
Phase II and Phase III SERM resistance. Drug
resistance to SERMs occurs when the ER survival
signal transduction pathway is blocked.
Surviving cancer cells create enhanced cell sur-
face signaling mechanisms (HER2/neu, EGFR)
that initiate phosphorylation cascades that
enhance the activity of the SERM ER complex
either directly or indirectly through transforming
growth factor β (TGFβ) and inducing coactiva-
tors that are phosphorylated. Long-term SERM
exposure creates sophisticated, yet vulnerable,
survival pathways that can be collapsed rapidly
by estradiol with a loss of HER2/neu signaling
and loss of prosurvival NFκB. The events that her-
ald apoptosis occur in parallel during estradiol
treatment. The death receptor fas is translated
and a cascade of caspase activation condens-
es the chromatin and destroys the cell.
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description of models of extended antihormonal therapy now
provide new opportunities for reusing the ER as a novel thera-
peutic target in cancer (Figure 3).
The repeated transplantation of MCF-7 tamoxifen-resistant
breast tumors into successive generations of tamoxifen-treated
athymic mice or culture of MCF-7 cells under estrogen-free con-
ditions with or without raloxifene results in the alteration of the
signal transduction pathways for estrogen (Liu et al., 2003; Yao
et al., 2000). Although estrogen is considered to be a survival
hormone with the ability to initiate replication, drug resistance to
estrogen deprivation occurs by developing cells with enhanced
survival pathways that maintain the growth advantage for can-
cer cells. For example, cell surface signaling through HER2/neu
is regulated by estrogen: without estrogen, HER2/neu mRNA is
increased (Newman et al., 2000).
Exhaustive antiendocrine therapy causes the ultimate form
of drug resistance, spontaneous growth (Figure 3). However,
studies in the laboratory (Yao et al., 2000) and preliminary clini-
cal studies (Lonning et al., 2001) demonstrate that estrogen,
rather than acting as a growth stimulus, acts as an apoptotic
agent through an ER-mediated mechanism in Phase II and
Phase III resistant disease (Figure 3).
Clearly, there is potential to incorporate an “estrogen purge”
into the long-term clinical treatment program. Laboratory stud-
ies already demonstrate that tumors that recur after estrogen-
induced apoptosis are again sensitive to the antitumor actions
of tamoxifen or estrogen withdrawal (aromatase inhibitor) (Yao
et al., 2000). A strategy of cyclical antihormone treatment and
estrogen purges may maintain patients with breast cancer for
decades.
Molecular mechanisms of estrogen-induced apoptosis
Preliminary subcellular studies have identified the fas/fas ligand
pathway as a putative mediator of estrogen-induced apoptosis
in both long-term estrogen-deprived cells (a model of aro-
matase inhibition) (Song et al., 2001) and either tamoxifen- or
raloxifene-resistant breast cancer cells (Liu et al., 2003; Osipo
et al., 2003). The cancer cell survival pathways mediated by the
HER2/neu cell surface signaling mechanisms collapse and so
does the nuclear NFκB transcription mechanism. In parallel,
estrogen induces the fas receptor (Liu et al., 2003; Osipo et al.,
2003) that may herald apoptosis (Figure 4).
Overall, these studies provide an insight into the balance of
cell survival and apoptosis that occurs through the ER.
However, the unanticipated result that the pure antiestrogen ful-
vestrant blocks the estrogen-induced apoptotic pathway and
enhances robust tumor growth by maintaining survival path-
ways (Osipo et al., 2003) illustrates the delicate balance
between survival and cell death governed by the ER. A similar
phenomenon occurs in the long-term estrogen-deprived cell
line MCF-7:5C (Lewis et al., 2004). Estrogen induces rapid
apoptosis in vitro and in vivo when autonomously growing cells
are transplanted into athymic mice. However, the combined
effect of the antiestrogen fulvestrant alone and the apoptotic
effect of estrogen alone results in maximal growth of MCF-7:5C
cells when both estrogen and fulvestrant are incubated together
(unpublished data). It is also possible to provoke estrogen-inde-
pendent growth in another breast cancer cell line T47D stably
transfected with the cDNA for PKC α. Tumors grow sponta-
neously in athymic mice, but again estrogen rapidly causes
tumor regressions through apoptosis (Chisamore et al., 2001).
Overall, it seems that a new general principle is emerging
where the creation of an enhanced survival network in the can-
cer cell can be rapidly destroyed by the use of estrogen targeted
to the ER. Discovery of the cellular survival mechanisms that
subvert the central role of the ER in breast cancer may provide
new advances in targeted therapies. Currently, the observation
that half of the ER-positive breast cancers are responsive to
antihormones could be viewed as an opportunity to restrict sur-
vival selectively with novel tyrosine kinase inhibitors and then
activate the ER with either traditional or low-dose estrogen. The
ER could also be used as the bait to discover a novel apoptotic
target to exploit in future drug discovery.
Summary of SERM prospects
The successful therapeutic application of antihormonal strate-
gies with tamoxifen and aromatase inhibitors has probably
reached its zenith in the clinic, but study of drug resistance has
now opened a new chapter in targeting cancer.There is current-
ly a separation of objectives, with the aromatase inhibitors being
used predominantly to treat breast cancer and the SERMs pro-
viding therapeutic opportunities as safer “hormone replace-
ment” therapies to prevent osteoporosis and reduce breast and
endometrial cancer (Figure 1). Nevertheless, extended or per-
haps indefinite treatment regimes are now possible if late-
phase antihormonally resistant disease can be destroyed with a
short estrogen purge. Additionally, there are practical opportuni-
ties to broaden the value of the ER as a therapeutic target by
devising logical treatment strategies for the patient with an ER-
positive tumor that is refractory to antihormonal treatment.
Although these new treatment options could potentially benefit
patients, it is the potential of the ER to identify a novel apoptotic
target that could dramatically advance selectivity in molecular
therapeutics.
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